about
A new strategy to fight antimicrobial resistance: the revival of old antibioticsThe combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosisTuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected childrenStrategies for potentiation of ethionamide and folate antagonists against Mycobacterium tuberculosisMycobacterium tuberculosis folate metabolism and the mechanistic basis for para-aminosalicylic acid susceptibility and resistanceNew insights into TB physiology suggest untapped therapeutic opportunitiesTuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapyGetting to 90-90-90 in paediatric HIV: What is needed?Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program.para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosisA randomized trial of prolonged co-trimoxazole in HIV-infected children in AfricaBacterial conversion of folinic acid is required for antifolate resistance.Tuberculosis treatment and drug regimens.Sulfamethoxazole susceptibility of Mycobacterium tuberculosis isolates from HIV-infected Ugandan adults with tuberculosis taking trimethoprim-sulfamethoxazole prophylaxis.Importance of the genetic diversity within the Mycobacterium tuberculosis complex for the development of novel antibiotics and diagnostic tests of drug resistancePharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of TuberculosisIn vitro susceptibility of Mycobacterium tuberculosis to trimethoprim and sulfonamides in FranceReconsidering some approved antimicrobial agents for tuberculosis.Cotrimoxazole prophylaxis and tuberculosis risk among people living with HIV.Is repositioning of drugs a viable alternative in the treatment of tuberculosis?Counterattacking drug-resistant tuberculosis: molecular strategies and future directions.The potential role of trimethoprim-sulfamethoxazole in the treatment of drug-resistant tuberculosis.Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrug-resistant Mycobacterium tuberculosisBacterial infection imaging with [18F]fluoropropyl-trimethoprim.Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform.Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.Identification of antimicrobial activity among new sulfonamide metal complexes for combating rapidly growing mycobacteria.Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis.Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.Sulfamethoxazole enhances the antimycobacterial activity of rifampicin.Mycobacterium tuberculosis and sulfamethoxazole susceptibility.8-Mercaptoguanine Derivatives as Inhibitors of Dihydropteroate Synthase.Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.Purine biosynthesis is the bottleneck in trimethoprim-treated Bacillus subtilis.
P2860
Q21131083-4931B121-AB69-4C89-BAF3-6D854B0DC38DQ24633894-3B90BF9E-BA54-448B-9B1E-19723E8710A9Q26774267-8090526C-20EA-4E35-A6B6-030E86A6A135Q27003186-138033B9-070C-4F1A-8313-2E3A4F6A7451Q28082718-D6241708-AF7C-4E55-8482-03BB44C5831CQ28388477-9FD54EE7-A35C-476F-B416-1F9A6B56B21CQ28602123-2E682F63-FB91-4DDF-BA94-97BD5CD17F18Q30385352-7CE6E531-E43A-4EE2-ACB3-4C5B45A7A04CQ33622785-3F13AE55-A6B3-42FD-B2E2-90F79869E8E4Q33869315-FCEF8E08-352D-4535-B0F1-4E4A0488698FQ34351796-59CFBED9-2AB8-4837-AB4D-E191223521E1Q34687538-91D1FEC9-810B-4FC3-992A-008F28D86E07Q34869548-EB7C6367-F239-4263-93BC-AADE72BC5E46Q35663866-4454F410-8000-40A5-BBC9-F0515367404BQ35960967-7DD0AD6B-0384-4AFE-8D48-597644309A9FQ36396241-3592693E-5C88-4284-97D0-7E8ECC3EE467Q37023099-C4CD0112-0545-4B36-82B7-C433BFFDF58BQ37335885-11A2091B-BAB4-4536-8082-8BDB352523CFQ37409878-7794B5E9-5564-4418-B00F-7DAF26519F27Q37452075-88C8AB76-F7E9-47E0-AE92-780B3B2037BAQ38053000-B71CB0C8-91F0-48F7-A673-FCED8679C525Q38547598-43B375DE-BB89-4827-ABE0-1E71204B73AFQ38806183-E09B8208-AA30-48F7-9CDB-862B33CC374AQ38872771-A2B3C6DB-4D67-469A-A237-A1ACE5E684D7Q38954085-C8FC8A6C-CF38-4D97-9818-6D89369A4F0AQ40131134-A1AF6C3D-1B0B-4973-B476-95A02D18B2BCQ40343712-FC2F20C2-07DD-4A05-93B0-98934B998168Q40475389-EACE29E2-1113-40DD-B801-773944955A42Q40560940-E7041D7B-0CCE-4899-81A7-CF8ABF43746EQ42376148-58B68ED5-F86F-418D-AFEC-F353CC521137Q42421215-B1811DA0-30AE-410D-A077-290B559741EDQ42716610-AB5A7891-041D-4F08-97AA-710542A6FDDEQ42770076-2403351E-50E4-4DD6-9003-312AC7B291AAQ48241249-FBB5E768-ABAA-4D20-8E8B-D84CA166C7B7Q50780166-6B7C77B4-2695-4938-88AD-5DD6716679CEQ51689526-08BD316D-EB99-453D-B4DC-786ECE6EAE8B
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Tuberculosis and trimethoprim-sulfamethoxazole
@ast
Tuberculosis and trimethoprim-sulfamethoxazole
@en
Tuberculosis and trimethoprim-sulfamethoxazole
@nl
type
label
Tuberculosis and trimethoprim-sulfamethoxazole
@ast
Tuberculosis and trimethoprim-sulfamethoxazole
@en
Tuberculosis and trimethoprim-sulfamethoxazole
@nl
prefLabel
Tuberculosis and trimethoprim-sulfamethoxazole
@ast
Tuberculosis and trimethoprim-sulfamethoxazole
@en
Tuberculosis and trimethoprim-sulfamethoxazole
@nl
P2093
P2860
P3181
P356
P1476
Tuberculosis and trimethoprim-sulfamethoxazole
@en
P2093
Glenn D Roberts
Leslie Hall
Mark L Silverman
Nancy L Wengenack
Pierre Forgacs
Sarah K Zimmerman
P2860
P304
P3181
P356
10.1128/AAC.01658-08
P407
P577
2009-11-01T00:00:00Z